Recurrent High Risk Myelodysplastic Syndrome Not Yet Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0092721 (Recurrent High Risk Myelodysplastic Syndrome)Not Yet Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs